Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Olema Pharmaceuticals (OLMA) Receivables - Other (2021 - 2026)

Olema Pharmaceuticals (OLMA) has 6 years of Receivables - Other data on record, last reported at $3.3 million in Q1 2026.

  • On a quarterly basis, Receivables - Other rose 72.97% to $3.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.3 million, a 72.97% increase, with the full-year FY2025 number at $3.1 million, up 47.97% from a year prior.
  • Receivables - Other reached $3.3 million in Q1 2026 per OLMA's latest filing, up from $3.1 million in the prior quarter.
  • Over the last five years, Receivables - Other for OLMA hit a ceiling of $3.3 million in Q1 2026 and a floor of $221000.0 in Q2 2023.
  • A 5-year average of $1.3 million and a median of $687000.0 in 2024 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: fell 8.32% in 2023, then surged 271.49% in 2024.
  • Tracing OLMA's Receivables - Other over 5 years: stood at $319000.0 in 2022, then skyrocketed by 110.97% to $673000.0 in 2023, then soared by 215.01% to $2.1 million in 2024, then skyrocketed by 47.97% to $3.1 million in 2025, then grew by 5.87% to $3.3 million in 2026.
  • Business Quant data shows Receivables - Other for OLMA at $3.3 million in Q1 2026, $3.1 million in Q4 2025, and $2.1 million in Q3 2025.